• MSR215 Using Machine Learning to Enable Timely Postpartum Care by Reliably Detecting Deliveries

    Dec 1, 2025, 00:00

  • MSR130 Improving Indirect Treatment Comparisons via an Alternative MAIC Patient Weighting Method

    Dec 1, 2025, 00:00

  • SA9 AI in Pragmatic Literature Reviews: A Scoping Review of Current Guidance and Development of a Framework for Integration

    Dec 1, 2025, 00:00

  • EE17 A Cost-Utility Analysis of Sparsentan for the Treatment of Immunoglobulin A Nephropathy in the UK

    Dec 1, 2025, 00:00

  • EE78 Broader Economic Effects of Investment in Cancer Control in Commonwealth Countries

    Dec 1, 2025, 00:00

  • EPH259 Trends and Characteristics of Thrombectomy Use in Acute Ischemic Stroke in Germany (2019-2024): Insights From National Claims Data

    Dec 1, 2025, 00:00

  • EPH271 Unmet Needs in Late-Line Metastatic Colorectal Cancer in Portugal: An Expert-Informed Epidemiological Forecast

    Dec 1, 2025, 00:00

  • EE543 Impact of Temporarily Implanted Nitinol Device in the Treatment of Urinary Symptoms in Patients With Benign Prostatic Obstruction in Spain

    Dec 1, 2025, 00:00

  • MSR137 Leveraging NLP to Characterize Real-World Triptan Use and Adherence From Unstructured EHR

    Dec 1, 2025, 00:00

  • MSR31 Applying Simulation-Guided Trial Design Principles to Prospectively Plan Target Trial Emulation of a Cluster Randomized Trial for Vaccine Coverage

    Dec 1, 2025, 00:00

  • EE372 Economic Evaluation of a Booster Dose of TDaP Vaccine to Adolescents in Spain

    Dec 1, 2025, 00:00

  • EE15 A Cost-Minimization and Budget Impact Analysis of NT-proBNP Screening Test for Risk Assessment and Monitoring of Pulmonary Arterial Hypertension (PAH) Patients in Australian Healthcare Setting

    Dec 1, 2025, 00:00

  • HSD97 Real-World Treatment Patterns Among Patients With Relapsed or Refractory (R/R) NPM1 Mutated (NPM1m) Acute Myeloid Leukemia (AML) in the United States (US)

    Dec 1, 2025, 00:00

  • HSD114 Treatment Characteristics of Breast Cancer Patients per HER2/HR Status in the United States: A Surveillance, Epidemiology, and End Results (SEER) 2018-2022 Database Analysis

    Dec 1, 2025, 00:00

  • CO133 Identifying Dogs to Be Screened for Canine Chronic Kidney Disease (cCKD)

    Dec 1, 2025, 00:00

  • EE102 Budget Impact and Clinical Outcomes of Energy- and Nutrient-Dense Formulas in Pediatric Disease-Related Malnutrition: A Middle Eastern Analysis

    Dec 1, 2025, 00:00

  • EE348 Early Stage Health Economic Evaluation of IMMUTOL Gene Therapy for Relapsing/Remitting Multiple Sclerosis in the Netherlands

    Dec 1, 2025, 00:00

  • RWD128 Obesity and MASH in the UK

    Dec 1, 2025, 00:00

  • RWD75 Epidemiology of Pulmonary Arterial Hypertension In Fran A Real-World Study Using the French National Healthcare Database (SNDS)

    Dec 1, 2025, 00:00

  • P27 Predicting Treatment Effect on the Loss of Ability to Rise From Floor in Duchenne Muscular Dystrophy Using Individual Trajectories: An Application of Joint Modeling in FOR-DMD

    Dec 1, 2025, 00:00

  • MT16 Evaluating Digital Health Tools in the UK for Type 1/2 Diabetes: An Overview of the Evidence Critiques

    Dec 1, 2025, 00:00

  • HTA246 Navigating Large Evidence Bases for MTEP Submissions

    Dec 1, 2025, 00:00

  • MT25 Hope and Acceptance of AI-Guided Psychotherapy: Patient Adoption of Conversational AI in Mental Health Care

    Dec 1, 2025, 00:00

  • CO223 Symptom Relief With Vonoprazan Treatment in Gastroesophageal Reflux Disease Patients With Diabetes in China: Post Hoc Analysis of the VIEW Study

    Dec 1, 2025, 00:00

  • CO198 Quantifying the Therapeutic Benefit of External Beam Radiotherapy in Uterine Serous Carcinoma: A Real-World Study

    Dec 1, 2025, 00:00

  • MSR122 How Far Have We Come With EQ-5D-5L Value Sets? An Updated Systematic Literature Review of 55 Valuation Studies

    Dec 1, 2025, 00:00

  • EE186 Cost per Responder of TAR-200 vs. Other FDA-Approved Novel and Generic Treatments Among Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer With Carcinoma in Situ in the United States

    Dec 1, 2025, 00:00

  • HTA267 Patient-Centered Hearing Technology Assessment: Integrating ICF Into Multicriteria Decision Making

    Dec 1, 2025, 00:00

  • EPH74 Epidemiological Burden of Osteoarthritis in Eastern, Central, and Western Europe Between 1990 and 2021

    Dec 1, 2025, 00:00

  • EPH4 A Person-Centered Approach: Exploring Social Support Network and Mental Health Among Shoebox House Residents in Hong Kong

    Dec 1, 2025, 00:00

  • PCR50 Comparison of Clinical Outcome Assessment in Randomized Controlled Trials and in Observational Studies for Amyotrophic Lateral Sclerosis: A Scoping Review

    Dec 1, 2025, 00:00

  • HPR193 The Alignment Between Technology Incorporations and Actual Health Needs

    Dec 1, 2025, 00:00

  • HPR103 From Evidence to Enforcement? Implications of the 2025 SVR Report for Pharmaceutical Pricing and Orphan Drug Policy in Germany

    Dec 1, 2025, 00:00

  • SA75 Performance of Large Language Model Clinical Data Extraction by Data Domain: A Rapid Systematic Review

    Dec 1, 2025, 00:00

  • HSD80 Organizational Support in Adopting New Treatments for Generalized Myasthenia Gravis

    Dec 1, 2025, 00:00

  • EE452 Exit Strategies in Patients With Stable MS: Cost-Effectiveness of Extended Interval Dosing of Ocrelizumab and Natalizumab vs. De-escalating to Cladribine

    Dec 1, 2025, 00:00

  • SA28 Decoding Diagnosis Delay in Juvenile Idiopathic Arthritis (JIA)

    Dec 1, 2025, 00:00

  • EPH251 The PHEBUS Study: A Retrospective Analysis of the Burden of Pneumococcal Infections in the Pediatric Population Using the French Hospital Discharge Database (PMSI)

    Dec 1, 2025, 00:00

  • HPR62 Do Patient-Reported Outcomes Influence Drug Prices? Evidence From the Italian Pricing and Reimbursement System

    Dec 1, 2025, 00:00

  • CO173 OncoLlama: Quantifying Cancer Inequalities at Population Scale Using Large Language Models for Clinical Text Abstraction

    Dec 1, 2025, 00:00

  • HPR152 Orphan Drug Approvals in the US and Europe: A 2-Year Comparison

    Dec 1, 2025, 00:00

  • OP18 Overview of Hospital Management of Patients Treated With Thoracic Endovascular Repair (TEVAR) and Revascularization of the Left Subclavian Artery in France Based on the PMSI

    Dec 1, 2025, 00:00

  • HTA182 How Will Patient Registry Data Play a Role in Joint Clinical Assessment (JCA) for Rare Diseases Learnings From National Health Technology Assessments (HTAs)?

    Dec 1, 2025, 00:00

  • EPH204 Real-life-Persistence to Antifibrotic Treatments in the French Population

    Dec 1, 2025, 00:00

  • HSD43 Environmental Impact of Intravenous vs. Oral Chemotherapy in Fran A 1000-Patient Model-Based Assessment

    Dec 1, 2025, 00:00

  • HTA318 The HTA Landscape of Orphan Products in the UK Between 2019 and 2024

    Dec 1, 2025, 00:00

  • EE532 Impact of Higher-Valent Pediatric Pneumococcal Vaccines on Antimicrobial Resistant Infections and Antibiotic Prescriptions in Greece

    Dec 1, 2025, 00:00

  • CO112 Evaluation of Health-Related Quality of Life (HRQoL) Among Patients Treated With Lifileucel After Progression on Immune Checkpoint Inhibitors (ICIs) and Targeted Therapies: Analyses From the C-144-01 Trial

    Dec 1, 2025, 00:00

  • CO263 Utility Values From Pooled Analysis of High Concentration (179 mg) Capsaicin Patch (HCCP) Studies In Peripheral Neuropathic Pain (PNP)

    Dec 1, 2025, 00:00

  • EPH194 Productivity Costs Due to Respiratory Infections in Denmark: A Potential for Prophylaxis

    Dec 1, 2025, 00:00

  • HPR92 Factors Impacting GKV Rebates for Orphan Drugs (OD) in Germany: A Decision Analysis Using the CRA RADAR Database

    Dec 1, 2025, 00:00

  • PT5 Pulmonary Nodule (PN)-Related and Lung Cancer-Related Workup Costs Within the Two-Year Period After Diagnosis of a PN in the United States

    Dec 1, 2025, 00:00

  • EE303 Cost-Utility Analysis of Iptacopan vs. C5 Inhibitors in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria Naïve to Complement Inhibitors in the Brazilian Private Healthcare System

    Dec 1, 2025, 00:00

  • PCR67 Effectiveness of Vonoprazan on Health-Related Quality of Life and Sleep Quality in Chinese Patients With Reflux Esophagitis: Post Hoc Analysis of the VIEW Study

    Dec 1, 2025, 00:00

  • EE295 Cost-Utility Analysis (CUA) of Sepiapterin for Treatment of Phenylketonuria (PKU)

    Dec 1, 2025, 00:00

  • CO81 Economic and Clinical Burden of Diagnosed Congenital Cytomegalovirus Disease in France During the First 2 Years of Life

    Dec 1, 2025, 00:00

  • PT42 Comparative Effectiveness of Second-Line Antidiabetic Medications on the Risk of Major Adverse Cardiovascular Events: A Real-World Study in China

    Dec 1, 2025, 00:00

  • CO56 Comparative Efficacy of Asciminib vs. Second-Generation TKIs in Newly Diagnosed PhCML Using Unanchored Matching-Adjusted Indirect Comparisons

    Dec 1, 2025, 00:00

  • EE181 Cost of Illness Study: Cushing's Syndrome in the Kingdom of Saudi Arabia

    Dec 1, 2025, 00:00

  • RWD13 AI for Precision Oncology Eviden Case Study Research From British Columbia, Canada

    Dec 1, 2025, 00:00

  • HTA325 The Perils of Treatment Crossover in Clinical Trials

    Dec 1, 2025, 00:00

  • HPR57 Distributional Cost-Effectiveness Analysis Across the Globe: How Feasible Is It Really?

    Dec 1, 2025, 00:00

  • HTA335 The Use of Real-World Evidence in Health Technology Assessment and the Application of the NICE RWE Framework: A Review of NICE Technology Appraisals

    Dec 1, 2025, 00:00

  • EE515 Healthcare Resource Utilization and Economic Burden Among Caregivers of Individuals With Autism Spectrum Disorder Caregiver: Findings From the 2024 5EU National Health and Wellness Survey

    Dec 1, 2025, 00:00

  • HTA332 The Soft Science in Hard Decisions: Utility of Qualitative Evidence in HTA Decisions

    Dec 1, 2025, 00:00

  • HPR104 From Policy to Practi Are Larger Member States Leading the Way for Joint Clinical Assessments?

    Dec 1, 2025, 00:00

  • PCR219 Socioeconomic Burden of Pulmonary Arterial Hypertension on Patients and Caregivers in the Czech Republic

    Dec 1, 2025, 00:00

  • MSR169 Predicting Outcomes and Estimating Minimum Sample Sizes for Divozilimab Efficacy in NMOSD: A Clinical Trial Simulation and Unanchored Matching-Adjusted Indirect Comparison

    Dec 1, 2025, 00:00

  • HTA105 Determinants of Willingness to Pay Thresholds in NICE Oncology Technology Appraisals

    Dec 1, 2025, 00:00

  • PCR65 Diagnostic Odyssey of Patients With the Rare Immunodeficiency-Activated PI3 Kinase Delta Syndrome (APDS): Case Study With Expert Interviews and Patient Surveys

    Dec 1, 2025, 00:00

  • EPH155 KRAS Alterations in Advanced Non-Small Cell Lung Cancer (NSCLC): Temporal Trends in Testing Patterns and Targeted Treatment Use Across Europe Between 2018 and 2024

    Dec 1, 2025, 00:00

  • EE25 A Novel View on the Treatment Costs of Relapsed or Refractory Diffuse Large B-cell Lymphoma From the Brazilian Private Healthcare System Perspective: A First- to Third-Line Analysis

    Dec 1, 2025, 00:00

  • RWD149 Real-World Burden of Illness in Patients With ER+/HER2- ABC Receiving Second-Line Treatment: Interim Results of Longitudinal Health Utility Data

    Dec 1, 2025, 00:00

  • EE250 Cost-Effectiveness of Familial Hypercholesterolemia Cascade Testing in Thailand: A Comparative Analysis of Exome vs. Long-Read DNA Sequencing

    Dec 1, 2025, 00:00

  • EE284 Cost-per-Remission of Vedolizumab vs. Risankizumab for the Treatment of Moderate-to-Severely Active Crohn’s Disease in Italy, France, and Canada

    Dec 1, 2025, 00:00

  • PCR182 Patient-Reported Outcomes After Total Knee Arthroplasty: Comparisons Across TKA Procedures and PRO Domains

    Dec 1, 2025, 00:00

  • P36 The Value of the Health and Well-being Benefits of Healthcare Facilities Outdoor Spaces

    Dec 1, 2025, 00:00

  • MSR146 Metamodels SHAP Analysis: Unearthing Data Interactions

    Dec 1, 2025, 00:00

  • HSD34 Digital Divide in Health Information Seeking: Rural and Urban Differences in the Use of Online Health Tools in the United States

    Dec 1, 2025, 00:00

  • HTA260 Optimizing PICO Scoping in EU HTA: Lessons From a HTA Coordination Group PICO Exercise in Advanced NSCLC to Inform Future Best Practice

    Dec 1, 2025, 00:00

  • EPH149 Integrated Sustainability Assessment of the Population-Based Colorectal Cancer Screening Program in Flanders

    Dec 1, 2025, 00:00

  • ISPOR Europe 2025: Powering Value and Access Through Patient-Centered Collaboration

    Dec 1, 2025, 00:00

  • HTA245 Navigating Joint Clinical Assessment in Europe: Strategic Roadmap and Recommendations for Health Technology Developers

    Dec 1, 2025, 00:00

  • PCR159 Mental and Behavioral Health Disorders MBHD Among Patients With Metastatic and Nonmetastatic Cancer: A Claims-Based Analysis

    Dec 1, 2025, 00:00

  • SA90 Systematic Review of Doubly Robust Methods for Population-Adjusted Indirect Comparisons

    Dec 1, 2025, 00:00

  • EPH75 Epidemiological Characteristics and Economic Burden of IgA Nephropathy—a Retrospective Study Using Multicenter Electronic Medical Records Data in China

    Dec 1, 2025, 00:00

  • EE144 Comparison of the Environmental Impact of Subcutaneous vs. Oral Therapies

    Dec 1, 2025, 00:00

  • HPR213 The Role of Regulatory Entities in Global Vaccine Availability

    Dec 1, 2025, 00:00

  • CO244 The Incidence and Economic Impact of Major Adverse Events Associated With Intravascular Temperature Management: A Systematic Review, Analysis, and Model

    Dec 1, 2025, 00:00

  • EE599 Optimization of the EVAR Pathway: An Integrated Organizational Model for Clinical Efficiency and Economic Sustainability

    Dec 1, 2025, 00:00

  • PCR14 Advancing Patient-Centered Value Assessment in Inherited Retinal Diseases: Leveraging EQ-5D-5L Vision Bolt-ons to Support IRD-Specific PROMs

    Dec 1, 2025, 00:00

  • HTA60 Budget Impact Minimization Approaches Used Across Europe, Brazil, and Japan in the Reimbursement of Obesity Medications

    Dec 1, 2025, 00:00

  • PT37 Economic Evaluation of I-Medicine: An AI-Driven E-Medicine Platform for Reducing Adverse Drug Reactions and Healthcare Expenditures

    Dec 1, 2025, 00:00

  • MSR224 Which Generative AI Method Is Used for High Specificity? A Methodological Comparison From the Systemic Literature Review of the Burden of Influenza in France

    Dec 1, 2025, 00:00

  • MT34 Patient Acceptance of Health Information Technologies: Comparative Insights From Wearables, TelE-Medicine, and mHealth

    Dec 1, 2025, 00:00

  • HTA327 The Preferences for Advanced Therapy Medicinal Products: A Multicriteria Decision Analysis Framework

    Dec 1, 2025, 00:00

  • PCR237 The Mental Health Burden of Rare Diseases Based on Insights From Patients and Caregivers Through Rarepulse® Social Listening

    Dec 1, 2025, 00:00

  • CO158 Leveraging Generative AI for Efficient Patient Safety Narrative Drafting: A Semaglutide Case Study

    Dec 1, 2025, 00:00

  • HTA89 CONITEC in Action: A Trend Analysis of CONITEC’s Evaluation Outcomes From 2020 to Present Day

    Dec 1, 2025, 00:00

  • RWD130 One Research Objective, Many Realities: Mapping Data Availability and Governance Diversity in Oncology Research

    Dec 1, 2025, 00:00

  • EPH70 Effects of Antidepressant Drug Classes on Dementia Risk: A 23-Year Cohort Study Using Akrivia Health Secondary Mental Health Data

    Dec 1, 2025, 00:00

  • EE631 Quantifying the Societal Value: Reduced Burden and Resource Savings From Baloxavir Marboxil's Influenza Transmission Protection in China

    Dec 1, 2025, 00:00

  • EE646 Regulatory Approval and Economic Evaluation of Tumor-Agnostic Therapies: A Comparative Study of Larotrectinib and Entrectinib

    Dec 1, 2025, 00:00

  • MSR4 A Layered Approach to Reducing Hallucinations in LLMs for Structured and Unstructured Clinical Data

    Dec 1, 2025, 00:00

  • PCR37 Capturing the Realities of Hematological Cancer Patients’ Experiences of Novel Immunotherapies: A Call for Alignment and Action to Improve PROM Within CAR-T and Bispecific Antibody Therapies

    Dec 1, 2025, 00:00

  • HSD115 Treatment Patterns for Unresectable Locally Advanced or Metastatic Hormone Receptor-Positive HER2-Negative and Triple-Negative Breast Cancers in France

    Dec 1, 2025, 00:00

  • EE729 The Working Dead? Why Longer Lives Can Seem Less Productive

    Dec 1, 2025, 00:00

  • HTA150 From Evidence Gaps to Launch Delays: A Review of Health Technology Assessment Critiques and Health Economics and Outcomes Research Strategy Readiness

    Dec 1, 2025, 00:00

  • HTA36 Application of Budget Impact Model in Evaluation of P2P Payment Strategy in US Health Systems

    Dec 1, 2025, 00:00

  • HSD62 Improving Patient Flow and Multidisciplinary Coordination in Urothelial Carcinoma: Insights From Bulgarian Oncologists

    Dec 1, 2025, 00:00

  • HTA232 Methodological Insights From Recent PBAC Recommendations to Support Biosimilar Reimbursement in Australia

    Dec 1, 2025, 00:00

  • HTA234 Mind the Gap: Divergent Perceptions of Patient Engagement Value in Health Technology Assessment (HTA) Among Healthcare Providers and Patient Advocacy Groups in Israel

    Dec 1, 2025, 00:00

  • EE82 Budget Impact Analysis of Direct Oral Anticoagulants vs. Vitamin K Antagonists in Algeria: A Public Payer Perspective

    Dec 1, 2025, 00:00

  • MSR44 Balancing Power and Interpretation: Responder Analysis vs. Mean Differences for PRO Endpoints in Oncology Clinical Trials

    Dec 1, 2025, 00:00

  • EPH77 Epidemiological Trends in HPV-Related Cancers and Diseases in the United Kingdom

    Dec 1, 2025, 00:00

  • CO52 Comparative Analysis of Patient-Reported Outcomes (PROs) in Asthma Biologic Late-Phase Studies and Approved Labels: Implications for Entry and Product Differentiation

    Dec 1, 2025, 00:00

  • EE583 Model Structure Variability in NICE HTAs: Evidence From Asthma and TMA Appraisals to Support the Need for Disease-Specific Reference Models

    Dec 1, 2025, 00:00

  • HSD4 Advancing Real-World Evidence in Diffuse Large B-cell Lymphoma: Insights From EHR-Derived Data in the UK

    Dec 1, 2025, 00:00

  • HTA163 Germany: Still a Benchmark for ATMP Access and Pricing: A Pricing Analysis of Germany's ATMP Landscape Compared to Other European Countries

    Dec 1, 2025, 00:00

  • EE588 Modeling Framework for Assessing Cost-Effectiveness of New Treatments in Chronic Kidney Disease

    Dec 1, 2025, 00:00

  • EE285 Costs and Health Outcomes of Meek Skin Micrografting vs. Mesh Skin Grafting in Adult Patients With Deep Partial Thickness and/or Full-Thickness Small (Burn) Wounds

    Dec 1, 2025, 00:00

  • HTA62 Budgetary Impact of Ultra-Rare Diseases in Brazil: A Review of Decisions From the Past Five Years

    Dec 1, 2025, 00:00

  • HPR165 Price-Volume Regulation in Fran Alignment Between Negotiated Thresholds With the French Economic Committee for Health Products (CEPS) and Real-World Observations

    Dec 1, 2025, 00:00

  • EPH76 Epidemiological Insights in Merkel Cell Carcinoma Across Europe: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • EPH111 Five-Year Inpatient Hospital Trends of COVID-19 Admissions in US Medicare Fee for Service

    Dec 1, 2025, 00:00

  • MSR82 Efficacy and Safety of Modern Biologics Compared to Conventional Therapies in AQP-4 Positive Neuromyelitis Optica Spectrum Disorder: A Fully AI-Automated Targeted Literature Review

    Dec 1, 2025, 00:00

  • CO1 A Balancing Act: Low-Dose Atropine Significantly Slows Pediatric Myopia Progression Without a Clinically Meaningful Risk of Rebound (Accelerated Myopia Progression Following Treatment Cessation)

    Dec 1, 2025, 00:00

  • EE51 Analysis of the Breast Cancer Diagnosis Program: A Window of Opportunity

    Dec 1, 2025, 00:00

  • SA67 Medical and Nonmedical Resource Utilization Associated With CIDP: Results From a Real-World International Survey

    Dec 1, 2025, 00:00

  • PT6 Real-World Effectiveness, Safety Economic Impact, and Humanistic Outcomes of Bispecific Antibodies (BsAbs) in Third-or-Later-Line (3L+) Treatment of Relapsed/Refractory (R/R) Large B-cell Lymphoma (LBCL): A Systematic Review and Meta-An ...

    Dec 1, 2025, 00:00

  • EE248 Cost-Effectiveness of Epigenetic Drugs in Oncology: A Systematic Review of Economic Evaluations

    Dec 1, 2025, 00:00

  • SA48 Graphical Evidence Frameworks to Visualize the Holistic Value of Healthcare Interventions

    Dec 1, 2025, 00:00

  • EE241 Cost-Effectiveness of ColonFlag in Austria: A Model-Based Evaluation

    Dec 1, 2025, 00:00

  • EE717 The Long-Term Cost-Effectiveness of Insulin Icodec vs. Once-Daily Basal Insulin Analogs in Italy

    Dec 1, 2025, 00:00

  • PCR211 Review of Patient Decision Aids for Psoriasis

    Dec 1, 2025, 00:00

  • PCR183 Patient-Reported Stigma Across Health Conditions: Insights From the National Health and Wellness Survey (NHWS) in China

    Dec 1, 2025, 00:00

  • HSD30 Current Treatment Pathway for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in England: Insights From a Qualitative Validation With Clinical Experts

    Dec 1, 2025, 00:00

  • HTA178 How Do National Systems Take the JCA Into Account Navigating Specificities to Achieve Accelerated Patient Access?

    Dec 1, 2025, 00:00

  • CO172 Nutritional Profile and Cost Evaluation of Elderly Patients in Home Care Within the Brazilian Private Health Sector: A Retrospective Study

    Dec 1, 2025, 00:00

  • CO100 EQ-5D Utility Impact of Worsening NYHA Class and CV Hospitalization (CVH) on Health-Related Quality of Life (HRQoL) of Patients With ATTR-CM Based on the ATTRibute-CM Trial

    Dec 1, 2025, 00:00

  • EE11 A Cost-Effectiveness Analysis of Ustekinumab Against Vedolizumab Among Inflammatory Bowel Disease Patients With Extra-intestinal Manifestations in Egypt

    Dec 1, 2025, 00:00

  • EE246 Cost-Effectiveness of Early Liquid Biopsy in Patients With Suspicious Metastatic Lung Cancer Alongside the LIBELULE Randomized Phase III Trial

    Dec 1, 2025, 00:00

  • EE343 Dominance in Economic Evaluation as a Leverage in Pharmaceutical Price Negotiation

    Dec 1, 2025, 00:00

  • HSD91 Rare Disease Awareness Among Physicians in Five European Countries: Results of a Cross-Sectional Survey

    Dec 1, 2025, 00:00

  • EPH42 Characteristics Associated With the Presence of a Functional Limitation Among Adults With Asthma in the United States: Findings From the Medical Expenditure Panel Survey Study

    Dec 1, 2025, 00:00

  • RWD92 Healthcare Resource Use and Mortality After Diabetic Ketoacidosis: Insights From Linked Primary- and Secondary-Care Data in the UK

    Dec 1, 2025, 00:00

  • EE190 Cost Comparison of Alternative Delivery Routes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA) in the English National Health Service (NHS)

    Dec 1, 2025, 00:00

  • HSD99 Receipt of Biomarker Testing in Non-Small Cell Lung Cancer: Using Real-World Data to Identify Testing Gaps and Treatment Characteristics

    Dec 1, 2025, 00:00

  • MSR40 Assessing Known Groups and Convergent Validity of the EQ-5D-5L in Assessing the Health-Related Quality of Life of Individuals With Obesity Who Have and Have Not Received Bariatric Surgery

    Dec 1, 2025, 00:00

  • EPH213 Sex Differences in Autoimmune Multimorbidity Across 11 Autoimmune Disorders in the Real-World Setting in Germany

    Dec 1, 2025, 00:00

  • EE114 Budget Impact of the VELYS™ Robotic-Assisted Solution Compared to Manual Procedure in Patients Undergoing Primary Total Knee Arthroplasty in Spain

    Dec 1, 2025, 00:00

  • EE710 The Hidden Clinical and Economic Costs of PPI Treatment Failures in Severe Erosive Esophagitis

    Dec 1, 2025, 00:00

  • HSD44 Environmental Impact of Psychiatric Outpatient Visit: Emissions Analysis of Travel and the Sustainability Potential of Remote Consultations

    Dec 1, 2025, 00:00

  • P51 Catalogue of Actions to Address Policy Barriers of Drug Repurposing

    Dec 1, 2025, 00:00

  • HPR72 EU HTA, Joint Clinical Assessment, and JCA Report: What Is the Possible Impact on Price Negotiation for Orphan Drugs in Germany?

    Dec 1, 2025, 00:00

  • EE695 The Cost-Effectiveness of Using Site-Specific Wastewater-Based Surveillance to Monitor COVID-19 in Long-Term Care Facilities

    Dec 1, 2025, 00:00

  • HTA276 Quality of Life and Productivity Costs in Cancer Patients Receiving Proton Therapy: A Predictive and Descriptive Study

    Dec 1, 2025, 00:00

  • PT14 The IMPACT Framework: A Value Assessment Framework for Holistic Health Technology Assessment

    Dec 1, 2025, 00:00

  • EE267 Cost-Effectiveness of Peripheral Neuropathy Screening in Malaysian Adults With Thalassemia: An Integrated Modeling Approach

    Dec 1, 2025, 00:00

  • HPR136 Mapping Access Pathways for New Medicines in Finland: A Real-World Review of HTA and Reimbursement Decisions

    Dec 1, 2025, 00:00

  • PT24 Comparative Analysis of Early Scientific Advice Mechanisms: EU JSC vs. National HTA Bodies (HAS, G-BA, NICE)

    Dec 1, 2025, 00:00

  • HTA331 The Safety and Effectiveness of Drug-Induced Sleep Endoscopy in Obstructive Sleep Apnea: A Systematic Review and Meta-Analysis

    Dec 1, 2025, 00:00

  • HTA340 Transportability of Overall Survival in Multiple Myeloma From the US to Germany: A Benchmarking Study

    Dec 1, 2025, 00:00

  • EPH14 Analysis of a Cancer Profile of 10 European States

    Dec 1, 2025, 00:00

  • EE608 Pharmacoeconomic and Healthcare Aspects of the TDM-Guided Decisions on Biological Treatment of Inflammatory Diseases: Systematic Review of International Evidence

    Dec 1, 2025, 00:00

  • HTA278 Real-World Evidence (RWE) and Its Impact on Scottish Medicines Consortium (SMC) Decisions: A Retrospective Review

    Dec 1, 2025, 00:00

  • EE525 Impact of Anosmia Severity on Health Utility Values in Chronic Rhinosinusitis With Nasal Polyps: An Exploratory Analysis From the WAYPOINT Trial

    Dec 1, 2025, 00:00

  • RWD174 Signal Detection and Network Pharmacology Analysis of Paronychia Associated With eGFR Inhibitors

    Dec 1, 2025, 00:00

  • EE388 Economic Evaluation of the Adoption of Peritoneal Dialysis for Newly Diagnosed Hemodialysis Ineligible Pediatric End-Stage Kidney Disease Patients in Egypt

    Dec 1, 2025, 00:00

  • HTA131 Evaluating GenAI for HTA Analogue Analysis: Identifying Rare Disease Approvals With Surrogate Endpoints and Single-Arm Trials

    Dec 1, 2025, 00:00

  • EE323 Developing a Multi-Indication Wider Societal Value Model to Estimate the Economic Impact of Semaglutide in Canada

    Dec 1, 2025, 00:00

  • CO29 Biomarker Levels in Patients With Crohn’s Disease Post-Advanced Therapy Induction: A Real-World Survey in Europe

    Dec 1, 2025, 00:00

  • MSR46 Beyond the Mean: Do Distribution-Based Metrics Offer Greater Insight Into Predictors of Societal Health Preferences? A Secondary Analysis of 42 EQ-5D-5L Value Sets

    Dec 1, 2025, 00:00

  • EPH274 Updated Projections of HPV Vaccine Coverage Growth in Europe: Are Countries on Track to Meet WHO's 2030 Target?

    Dec 1, 2025, 00:00

  • EPH263 Trends in Hospitalizations and Amputations in Diabetic Foot Ulcers (DFUs) in Germany 2019 to 2024

    Dec 1, 2025, 00:00

  • EE161 Cost-Effectiveness Analysis of Ga-PSMA-11 PET/CT Imaging Followed by Lu-PSMA-617 vs. Standard of Care in Metastatic Castrate-Resistant Prostate Cancer

    Dec 1, 2025, 00:00

  • CO72 Development of a Preliminary Conceptual Model to Capture the Adult Patient Experience of Follicular Lymphoma

    Dec 1, 2025, 00:00

  • EE591 Modeling What Matters: The Real-World Burden of Pregnancy-Related Complications in cTTP

    Dec 1, 2025, 00:00

  • CO138 Impact of Individualized Neoantigen Therapies on Health, Productivity, and Health System Capacity Outcomes in Resected Melanoma in Belgium

    Dec 1, 2025, 00:00

  • EE180 Cost of First-Line Treatment of Hepatocellular Carcinoma With the Immune Checkpoint Inhibitor-Based Regimens STRIDE and Atezolizumab Plus Bevacizumab in Brazil

    Dec 1, 2025, 00:00

  • MSR8 A Novel Framework to Assess Noninferiority in National Institute for Health and Care Excellence (NICE) Cost-Comparison Evaluations (CCEs) Where Network Meta-Analyses (NMAs) Report Nonstatistically Significant Differences

    Dec 1, 2025, 00:00

  • PCR168 Pain and Fatigue Assessment and Evaluation in Oncology Trials

    Dec 1, 2025, 00:00

  • RWD52 Data-Driven Alerts to Support the Care of People Living With Epilepsy and Provide an Infrastructure for the Development of Real-World Evidence

    Dec 1, 2025, 00:00

  • SA47 Global Trade Shocks and Exchange Rate Effects on Pharmaceutical Reference Pricing: Implications of EU Stimulus for US MFN Policy

    Dec 1, 2025, 00:00

  • EE336 Discrete Event Simulation and Treatment Sequencing Cost-Effectiveness Model in Second-Line Highly Active Relapse Remitting Multiple Sclerosis for a NICE Multiple Technology Appraisal

    Dec 1, 2025, 00:00

  • MSR147 Methods for Incidence Progression Estimation in Partitioned Survival Analysis: Does the Chosen Method Matter?

    Dec 1, 2025, 00:00

  • HSD101 Self-Reported Health Related Quality of Life (HRQoL) in Patients With Ischemic Heart Disease: A Randomized Controlled Trial on Digital Health Pharmacist Interventions

    Dec 1, 2025, 00:00

  • EE677 Systematic Literature Review of the Use of Generative AI in Health Economic Evaluation

    Dec 1, 2025, 00:00

  • CO114 Examining the Trade-off of Breastfeeding vs. Semaglutide Use After Childbirth

    Dec 1, 2025, 00:00

  • PCR105 Health Equity in Economic Analyses of Person-Centered Care: A Systematic Review

    Dec 1, 2025, 00:00

  • CO142 Impact of Tafamidis Use in Colombian Patients Diagnosed With ATTR-CM on Health-Related Quality of Life During One Year of Follow-up: Real-World Study in Colombia

    Dec 1, 2025, 00:00

  • MSR107 Facilitator-Led vs. Remote Components Within Structured Expert Elicitation of Survival Outcomes: A Targeted Review

    Dec 1, 2025, 00:00

  • SA96 The Use of Dynamic Models in Economic Evaluations in the UK and France

    Dec 1, 2025, 00:00

  • HTA308 Synthesizing Health Service Utilization Data for a Complex Intervention: A Case Study of Teledermatology

    Dec 1, 2025, 00:00

  • EE71 Baseline Risk Heterogeneity in Cost-Effectiveness Analysis of the Diabetes Prevention Program

    Dec 1, 2025, 00:00

  • EPH198 Public Health Impact of 25 Years of Pneumococcal Conjugate Vaccination in Children 5 Years Old: A Modeling Analysis

    Dec 1, 2025, 00:00

  • PCR87 Evolution of High-Efficacy Therapies for Relapsing Multiple Sclerosis: Does Innovation Meet Patient Preferences?

    Dec 1, 2025, 00:00

  • HPR116 Impact Of Reimbursement Policy On Medicines Expenditures And Copayment: The Case of Cardiovascular Medicines In Bulgaria

    Dec 1, 2025, 00:00

  • CO185 Preliminary Real-World Comparative Analysis of Trastuzumab Deruxtecan vs. Trastuzumab Emtansine in Second-Line HER2-Positive Metastatic Breast Cancer

    Dec 1, 2025, 00:00

  • MT44 Unraveling the Challenges of Multiplex Cell Culture Technology Using the HTA Core Model

    Dec 1, 2025, 00:00

  • MT30 Multi-Country Survey to Explore Clinicians Experiences on a New Imaging Technology for Gastrointestinal Endoscopes and Its Impact on Detection and Resection of Lesions

    Dec 1, 2025, 00:00

  • PCR210 Reliability Test of the Hungarian Versions of the Hypertension Knowledge Test and the QLICD-HY Quality of Life Assessment Questionnaire Among People With High Blood Pressure

    Dec 1, 2025, 00:00

  • MSR222 What Prompt Engineering Missed and How Context Engineering Fixes It

    Dec 1, 2025, 00:00

  • Physician-Directed Reinvestment: A Novel Cost-Savings Framework for Hospital Systems That Leverages Frontline Physicians

    Dec 1, 2025, 00:00

  • PCR185 Perspectives of Patients and Caregivers on Relapsed/Refractory Acute Myeloid Leukemia Treatments: A Mixed-Methods Interview Study

    Dec 1, 2025, 00:00

  • MSR93 Evaluating the Efficacy of Artificial Intelligence Models as Suitable Screening Tools in Systematic Reviews: The Example of Glucagon-Like Peptide-1 Receptor Agonists in Heart Failure Treatment

    Dec 1, 2025, 00:00

  • MSR91 Evaluating Bayesian Borrowing Methods for Treatment Effect Extrapolation: A Simulation-Based Study

    Dec 1, 2025, 00:00

  • HSD98 Real-World Treatment Patterns of US Patients With Platinum-Resistant Ovarian Cancer

    Dec 1, 2025, 00:00

  • EE754 What Tips the Scale Toward Reimbursement? A Dutch-led Comparison of Pharmacoeconomic Evaluations Across the Netherlands, Sweden, and the United Kingdom

    Dec 1, 2025, 00:00

  • HPR18 AI for Pricing Reimbursement: When to Green-Light, When to Red-Light?

    Dec 1, 2025, 00:00

  • EPH249 The Incidence, Mortality, and Survival of Nonmetastatic Colorectal Cancer (CRC) per TNM Stages in the United States: A Surveillance, Epidemiology, and End Results (SEER) 2018-2022 Database Analysis

    Dec 1, 2025, 00:00

  • PCR196 Psychometric Performance of EQ-HWB for Japanese Populations

    Dec 1, 2025, 00:00

  • HPR29 Assessing Stakeholders’ Perceptions of the EU Health Technology Assessment Regulation and Access to Innovative Medicines in Europe and the Netherlands: Challenges, Opportunities, and Recommendations

    Dec 1, 2025, 00:00

  • CO259 Use of Encorafenib + Cetuximab EC in Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer (mCRC) in Real-World Settings: Data Visualization From a Pooled Dataset of European Observational Studies

    Dec 1, 2025, 00:00

  • HTA11 A NICE Idea? Assessing the Impact of the Severity Modifier in Oncology and Nononcology Single Technology Appraisals

    Dec 1, 2025, 00:00

  • EE586 Modeled Number and Cost of Biparametric Magnetic Resonance Imaging (bpMRI) Examinations in a Nationwide Prostate Cancer Screening Program: Utilizing the Results of the Czech Prostapilot Study

    Dec 1, 2025, 00:00

  • HTA283 Reference Framework, Key Decision-Making Factors, and the Impact of Critical Parameters on Listing Recommendations for Nononcologic Drugs for Rare Diseases Issued by Canadian HTA Bodies

    Dec 1, 2025, 00:00

  • HTA273 Prefilled Syringes in Anesthesiology: A Quantitative Assessment of Economic and Organizational Outcomes

    Dec 1, 2025, 00:00

  • P9 Exploring Variability in EQ VAS Scores: A Systematic Review and Meta-Regression of Population Health Studies

    Dec 1, 2025, 00:00

  • PCR265 Wasfaty Improves Quality of Outpatient Pharmaceutical Service at a Tertiary Academic Hospital: A Descriptive Analysis

    Dec 1, 2025, 00:00

  • EE561 Is Lecanemab Worth the Wait? Real Option Value and the Cost of Future Innovation in Alzheimer's Disease

    Dec 1, 2025, 00:00

  • HTA272 Predicting SMC Appraisal Outcomes Using Machine Learning: A Model to Support Early Market Access Strategy

    Dec 1, 2025, 00:00

  • MT2 Adoption of AI Clinical Decision Support Systems in Primary Care: An Evaluation of Physician Acceptance

    Dec 1, 2025, 00:00

  • HPR70 ESMO-MCBS Evaluation and French Derogatory Access Decision: Is There a Correlation?

    Dec 1, 2025, 00:00

  • PCR249 Treatment Preferences in Adults With Chronic Spontaneous Urticaria in Italy: Insights From the CHOICE-CSU 2 Study

    Dec 1, 2025, 00:00

  • HSD7 Are Glucagon-Like Peptide-1 Receptor Agonists Prescribed for Weight Loss Slipping Through the Net of Japan’s Strict Guidelines? An Analysis of Health Insurance Claims Data

    Dec 1, 2025, 00:00

  • P28 Survival Time-Adjusted Indirect Comparisons: A New Methodology for Comparing Between Phases of Treatment in Early Cancer

    Dec 1, 2025, 00:00

  • RWD109 Integrating Mendelian Randomization With Real-World Eviden Cost-Effectiveness of Lipoprotein Testing for Primary Prevention of Cardiovascular Disease in High-Income Countries

    Dec 1, 2025, 00:00

  • PT1 A Contemporary Approach to Determining Cancer Patients Healthcare Resources Utilization

    Dec 1, 2025, 00:00

  • EPH57 Descriptive Statistics and Polysubstance Use of Pregnant Women Admitted to the United States Treatment Facilities With Methamphetamine Use

    Dec 1, 2025, 00:00

  • EPH58 Detection of a Potential Pericarditis Safety Signal Associated With Azithromycin: Evidence From FAERS Disproportionality Analysis

    Dec 1, 2025, 00:00

  • RWD182 Transforming Patient Journeys With Agentic AI

    Dec 1, 2025, 00:00

  • MSR103 Exploring Meaningful Change in Digital Health Technologies via Qualitative Interviews

    Dec 1, 2025, 00:00

  • EE625 Quantifying the Economic Burden of Osteoarthritis in Portugal: Insights From a Patient Journey Model

    Dec 1, 2025, 00:00

  • CO216 Safety and Efficacy of Antibody Drug Conjugate (ADCs) in Pretreated Locally Advanced/Metastatic (LA/m) Triple-Negative Breast Cancer (TNBC): Systematic Literature Review (SLR)

    Dec 1, 2025, 00:00

  • EE103 Budget Impact of a Minimally Invasive Surgical Treatment for Benign Prostatic Obstruction in Italian Healthcare Service

    Dec 1, 2025, 00:00

  • EE286 Costs and Healthcare Resource Utilization Associated With Generalized Myasthenia Gravis: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • MSR18 AI Assistant Meets Human: Refining Methods for Research-Tailored AI Assistants to Support Global Product Strategy, Decision Making, and HEOR Impact

    Dec 1, 2025, 00:00

  • EPH67 Economic and Epidemiological Burden of Type 1 Diabetes In France

    Dec 1, 2025, 00:00

  • CO217 Safety Profile of Semaglutide in Obesity Management With or Without Type 2 Diabetes (T2DM): A Systematic Literature Review From Controlled and Real-World Settings

    Dec 1, 2025, 00:00

  • HPR66 Early Impact of the Mazars Review on Reimbursement Timelines in Ireland

    Dec 1, 2025, 00:00

  • MT10 Comparing Robotic-Assisted Coronary Artery Bypass Grafting Using the Da Vinci Surgical System to a Nonrobotic Approach: A Systematic Literature Review and Meta-Analysis

    Dec 1, 2025, 00:00

  • OP25 Understanding the Needs and Aspirations of Emerging HEOR Talent: Results From the ISPOR New Professional and Student Survey

    Dec 1, 2025, 00:00

  • HPR174 Regulatory Timelines for CMA Medicines In Italy: A Comparative Analysis of Pricing and Reimbursement Procedures

    Dec 1, 2025, 00:00

  • RWD100 Improving Access to German Health Claims Data Through Synthetic Data Generation: Findings and Achievements of a Holistic Evaluation

    Dec 1, 2025, 00:00

  • HSD64 Integrating CEUS in Diagnostic Pathways: Evidence of Economic and Organizational Sustainability From the Italian Healthcare System

    Dec 1, 2025, 00:00

  • MSR80 Economic Valuation of Premature COVID-19 Mortality in Kuwait: A Comparative Analysis of Three Methodological Approaches

    Dec 1, 2025, 00:00

  • HPR206 The Innovative Licensing and Access Pathway (ILAP): Early Pathway Experience, Examining, Process Adaptations, and Industry Impact

    Dec 1, 2025, 00:00

  • HPR186 Socioeconomic Disparities in Access to Treatment for Major Depressive Disorder: The Role of Accumulator and Maximizer Insurance Plans

    Dec 1, 2025, 00:00

  • HSD53 From Diagnosis to Treatment: Evaluating Timeliness and Treatment Patterns in Czech Pancreatic Cancer Patients

    Dec 1, 2025, 00:00

  • HPR188 Solving the PICO Puzzle: Perspectives on Outcome Measures for Oncology Medicines in Assessments of the European Medicines Agency and Health Technology Assessment Organizations in Europe

    Dec 1, 2025, 00:00

  • EPH229 The Burden of Patients With Severe Asthma: A Comparison Between Patients Treated With and Eligible for Monoclonal Antibodies Through a Retrospective Observational Analysis of Italian Real-World Data

    Dec 1, 2025, 00:00

  • OP5 Economic and Organizational Impact of Subcutaneous Ocrelizumab in French Daily Hospitals

    Dec 1, 2025, 00:00

  • HTA184 HTA Conflicts in Europe: Agreeing to Disagree?

    Dec 1, 2025, 00:00

  • HPR43 Characterizing Medicines Reimbursed Under Managed Access Protocols in Ireland (2006-2025)

    Dec 1, 2025, 00:00

  • EE687 The Budget Impact and Time Savings of Introducing Subcutaneously Administered Nivolumab and Hyaluronidase (NIVO SC) to Patients Receiving Intravenously Administered Nivolumab (NIVO IV) Across Indications in Canada

    Dec 1, 2025, 00:00

  • SA17 Bigger, Better Studies: Prioritizing Literature Review Using an Approach Based on Large Language Models

    Dec 1, 2025, 00:00

  • HTA115 Do Short-Term Outcome-Based Payments for Treatments Provide the Same Incremental Net Benefit As List Price Discounts?

    Dec 1, 2025, 00:00

  • CO250 Therapeutic Benefit of Radiotherapy in Uterine Serous Carcinoma (USC): A Real-World Study

    Dec 1, 2025, 00:00

  • EE523 Human Metapneumovirus (hMPV): Systematic Literature Review of Economic and Humanistic Disease Burden in Adults

    Dec 1, 2025, 00:00

  • MSR204 Transparent, Traceable, and Reproducible Evidence Generation for HTA Using Generative AI and Retrieval-Augmented Generation (RAG)

    Dec 1, 2025, 00:00

  • EE490 Health Economic Assessment of Using Single-Operator Direct Visualization Cholangioscopy in the Management of Complex Bile Duct Stones in Saudi Arabia

    Dec 1, 2025, 00:00

  • HTA312 The 90-Day Ambition: Historical Analysis of 200 NICE Appraisals to Assess Proportion-Achieving Final Guidance Within 90 Days of MHRA Approval

    Dec 1, 2025, 00:00

  • PCR108 Health State Utilities Associated With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

    Dec 1, 2025, 00:00

  • CO7 Addressing the Inherent Challenges of the French National Claims Database (SNDS) Through Algorithms to Identify Patients With Diffuse Large B-cell Lymphoma (DLBCL) and Their Chemotherapy Treatments

    Dec 1, 2025, 00:00

  • HTA329 The Role of Environmental Evidence in HTA: Comparative Insights Into Global Assessment Frameworks

    Dec 1, 2025, 00:00

  • EPH33 Burden of Bloodstream Infections in the United States: Incidence and Healthcare Resource Utilization 2022-2024

    Dec 1, 2025, 00:00

  • MSR23 Ai-Augmented Data Extraction in Literature Reviews: Toward First-Pass Accuracy Competitive With Human Performance

    Dec 1, 2025, 00:00

  • HTA154 From JCA to Local PR: Evaluating Impact Across Europe

    Dec 1, 2025, 00:00

  • EE33 A Systematic Literature Review of Economic Evaluation Studies for Schizophrenia

    Dec 1, 2025, 00:00

  • RWD172 Sex Differences in Characteristics and Treatment Patterns of Patients With Sleep Disorders in South Korea

    Dec 1, 2025, 00:00

  • EPH38 Care of Patients With Phenylketonuria (PKU) in Germany a Claims Data Analysis From 2013 to 2023

    Dec 1, 2025, 00:00

  • PCR107 Health-Related Quality of Life Measured by EQ-5D Utility Among Patients With TGCT: A Trial-Based Analysis of EQ-5D Data From Patients in the MOTION Trial

    Dec 1, 2025, 00:00

  • CO247 The Relationship Between Surrogate Endpoints and Overall Survival in Myelofibrosis Clinical Trials: Results From a Targeted Literature Review

    Dec 1, 2025, 00:00

  • EE177 Cost of Adverse Events With the Bruton Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib in the First-Line Treatment of Chronic Lymphocytic Leukemia in Brazil

    Dec 1, 2025, 00:00

  • CO186 Preliminary Real-World Results of a Community Pharmacy-Based Intervention in COPD: Evidence From the Chronic Diseases From A to Z Program

    Dec 1, 2025, 00:00

  • EE428 Estimating the Public Health and Economic Impact of Recombinant Zoster Vaccine (RZV) Vaccination for Adults Aged 50 and Older in South Korea

    Dec 1, 2025, 00:00

  • HTA359 What Are the Likely PICOs for Tovorafenib and Lifileucel as the First Products to Go Through the JCA?

    Dec 1, 2025, 00:00

  • HSD38 Economic Burden and Healthcare Resource Utilization of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Germany: A Claims Data Analysis

    Dec 1, 2025, 00:00

  • HPR63 Does the Joint Clinical Assessment (JCA) Enable Health Equity Across Europe? A Review of HTA Practices in the EU

    Dec 1, 2025, 00:00

  • EE466 Financial Impact of Dementia Care on Thai Households: A Multicenter Study of Informal Care Costs and Contributing Factors

    Dec 1, 2025, 00:00

  • EE615 Price Behavior of Originator Adalimumab After Biosimilars Entry: Evidence From the Colombian Market

    Dec 1, 2025, 00:00

  • PT10 An Analysis of Possible Reference Countries for a US Most-Favored Nation Policy and the Associated Impact on the Global Pharmaceutical Industry

    Dec 1, 2025, 00:00

  • EE734 Treatment Failure Event Categories Reveal Progressive Increases in Disease and Economic Burden Among Patients With Major Depressive Disorder

    Dec 1, 2025, 00:00

  • PCR227 The Economic Burden of Amyotrophic Lateral Sclerosis: An Observational Study of Out-of-Pocket Expenses and the Impact on Caregivers

    Dec 1, 2025, 00:00

  • PCR125 Identifying Factors Associated With Involvement in Healthcare Decisions in Wales

    Dec 1, 2025, 00:00

  • PCR160 Mental Health Benefits of Exercise Variation: Evidence From the 2024 5EU National Health and Wellness Survey

    Dec 1, 2025, 00:00

  • HPR196 The Development of the Private Healthcare Sector in Romania Between 2005 and 2023

    Dec 1, 2025, 00:00

  • HTA133 Evaluating the Impact of Implementing AI-Assisted Contouring on Radiotherapy Staff and Workflows

    Dec 1, 2025, 00:00

  • HTA149 From Efficiency to Equity: Considerations in NICE Technology Appraisals

    Dec 1, 2025, 00:00

  • EE265 Cost-Effectiveness of Pegcetacoplan for the Treatment of Paroxysmal Nocturnal Hemoglobinuria in Patients With Treatment Failure After C5 Inhibitor Therapy: An Analysis From the Brazilian Public Healthcare System Perspective

    Dec 1, 2025, 00:00

  • EPH176 Persistence With Antidementia Therapy in Germany: A Retrospective Cohort Study of 212,850 Patients

    Dec 1, 2025, 00:00

  • HTA172 Health Technologies Using Artificial Intelligen What Is Being Assessed in the UK by NICE?

    Dec 1, 2025, 00:00

  • EPH235 The Fiscal Case for Investing in COVID-19 Vaccination: A UK Treasury Perspective

    Dec 1, 2025, 00:00

  • HTA330 The Role of Health-Related Quality of Life in German HTA Decisions: An Analysis of G-BA Assessments From 2020-2024

    Dec 1, 2025, 00:00

  • EE465 Financial and Mental Health Burden on Caregivers of Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD) in the United States

    Dec 1, 2025, 00:00

  • HTA68 Challenges and Opportunities in the Dutch Lock Procedure Improving Access and Reimbursement Timelines for Cell and Gene Therapies in the Netherlands

    Dec 1, 2025, 00:00

  • EE109 Budget Impact of Introducing an Omalizumab Biosimilar in 23 European Countries

    Dec 1, 2025, 00:00

  • HPR217 Three Systems, One Market? A Comparative Analysis of Medical Device Reimbursement in Germany, Austria, and Switzerland

    Dec 1, 2025, 00:00

  • EE145 Comparison of Time-Driven Activity-Based Costs Incurred by Patients and Caregivers Related to Intravitreal Injections for Retinal Vein Occlusion

    Dec 1, 2025, 00:00

  • RWD4 A Real-World Retrospective Study on the Utilization of Antifibrotic Drugs in Greece During the Period 2019-2023

    Dec 1, 2025, 00:00

  • CO256 UDCA Treatment Response in Primary Biliary Cholangitis in the United States

    Dec 1, 2025, 00:00

  • EE209 Cost-Effectiveness Analysis of Isavuconazole vs. Liposomal Amphotericin B for the Treatment of Invasive Mucormycosis in Morocco

    Dec 1, 2025, 00:00

  • EE60 Assessing the Cost-Effectiveness of Subcutaneous Semaglutide 2.4 mg in the Management of Individuals With Obesity and Prediabetes in England

    Dec 1, 2025, 00:00

  • PCR246 Translation and Psychometric Validation of Brief Illness Perception Questionnaire: The Urdu Version

    Dec 1, 2025, 00:00

  • EPH138 Important Risk Factors to Proxies of Treatment Failures in Patients With Major Depressive Disorder: Insights From a Claims Database Study

    Dec 1, 2025, 00:00

  • CO215 Roflumilast Foam 0.3% in Patients With Psoriasis of the Scalp and Body: Improvements in Patient-Reported Outcomes and Quality of Life

    Dec 1, 2025, 00:00

  • CO69 Delphi Panel for Standardizing Outcome Measures in Radical Prostatectomy Surgical Care Pathway

    Dec 1, 2025, 00:00

  • PCR204 Quantifying the Societal Burden of Acanthamoeba Keratitis: Results From a Patient Survey

    Dec 1, 2025, 00:00

  • EPH266 Uncovering Gender Disparities in Secondary Care for Major Adverse Cardiovascular Events (MACE): Insights From the Hospital Episodes Statistics (HES) Database

    Dec 1, 2025, 00:00

  • MSR6 A Multistate Framework for Analyzing Outcomes in Diffuse Large B-cell Lymphoma With Autologous Hematopoietic Stem Cell Transplant

    Dec 1, 2025, 00:00

  • EE524 Humanistic and Economic Burden of Primary Biliary Cholangitis: A Systematic Review of Health-Related Quality of Life Healthcare Resource Utilization and Associated Cost

    Dec 1, 2025, 00:00

  • MSR65 Country-Specific Adaptation of Health Economic Models With Generative AI: A Case Study in Alzheimer’s Disease

    Dec 1, 2025, 00:00

  • EE699 The Economic Burden of Diabetes-Related Blindness and Vision Impairment in Saudi Arabia

    Dec 1, 2025, 00:00

  • CO162 Matching-Adjusted Indirect Comparison Between Garadacimab and Donidalorsen for Long-Term Prophylaxis in Hereditary Angioedema

    Dec 1, 2025, 00:00

  • EPH7 A Real-World Survey of Health Inequalities as Drivers for Burden on Male Hemophilia Patients in the US, EU5, and Asia

    Dec 1, 2025, 00:00

  • EE502 Healthcare Expenditure for Treatment of Cardiovascular Disease Among Hypercholesterolemia Patients in Japan: A Claims Data Analysis

    Dec 1, 2025, 00:00

  • HPR179 Rising Costs in Pharmaceutical Services: A Decade of Prescription Spending Trends in Türkiye 2015-2024

    Dec 1, 2025, 00:00

  • EE595 Obstructive Sleep Apnea (OSA) Phenotypes and the Personalized Impact of Positive Airway Pressure (PAP) Therapy on Healthcare Resource Use

    Dec 1, 2025, 00:00

  • PCR54 Cross-Country Comparison of Cancer-Related Health Preferences Using the EORTC QLU C10D: Evidence Supporting Standardized Value Sets

    Dec 1, 2025, 00:00

  • EE354 Economic Burden and Unmet Need Among Adult Patients With Varying Patterns of Atopic Dermatitis: Results From the Adelphi Real-World Disease Specific Program

    Dec 1, 2025, 00:00

  • SA85 Simulating Patient Journeys in Heart Failure to Optimize Treatment Pathways: An Agent-Based Modeling Study

    Dec 1, 2025, 00:00

  • EE315 Cost Utility of Subcutaneous Methotrexate As a Second-Line Treatment for Moderate to Severe Rheumatoid Arthritis in the UK

    Dec 1, 2025, 00:00

  • EE80 Budget Impact Analysis of 68-Ga-PSMA-11 PET CT Imaging Followed by 177Lu-PSMA-617 Therapy in Metastatic Castrate-Resistant Prostate Cancer

    Dec 1, 2025, 00:00

  • EE605 Out-of-Pocket Expenditures of Families Affected by Epidermolysis Bullosa in Europe

    Dec 1, 2025, 00:00

  • MSR124 How Publication Bias May Overestimate the Risk of Serious Adverse Events Associated With Bisphosphonate Use

    Dec 1, 2025, 00:00

  • MSR121 How Does the Source of Transition Probabilities Influence Natural History Simulation and Economic Evaluation in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)?

    Dec 1, 2025, 00:00

  • HTA35 Applicability of the STEDI Value Framework to Vaccines in Health Technology Assessment: Opportunities and Considerations

    Dec 1, 2025, 00:00

  • EPH278 What Characteristics Are Associated With Having a Work Limitation Among United States Adults With Asthma?

    Dec 1, 2025, 00:00

  • EE86 Budget Impact Analysis of High-Energy High-Protein (HEHP) Oral Nutritional Support (ONS) for the Treatment of Disease-Related Malnutrition (DRM) in Cancer Patients in the French Community Setting

    Dec 1, 2025, 00:00

  • P31 Comparative Performance of the EQ-5D-5L and PROMIS-10 in the Elderly: Data From the EQ-DAPHNIE Project in Five Countries

    Dec 1, 2025, 00:00

  • CO141 Impact of Prenatal Exposure to Antidepressants on Adverse Birth and Pregnancy Outcomes: A Propensity-Scored Matched Retrospective Cohort Study Using a Large Electronic Medical Record Database 2012-2021

    Dec 1, 2025, 00:00

  • HPR80 Evolution of Manufacturer-Set List Prices and GKV Rebates for Orphan Drugs (OD) in Germany 2013-2024: How Much US WAC Is in German OD-Prices

    Dec 1, 2025, 00:00

  • HPR8 A Retrospective Analysis of Reimbursement Timelines in Ireland: What Does a 10-Year Analysis Show?

    Dec 1, 2025, 00:00

  • PT35 Cost-Effectiveness Analysis of Ribociclib Plus Endocrine Therapy for the Treatment of HR/HER2 Early Breast Cancer in Greece

    Dec 1, 2025, 00:00

  • PT34 A Transitional Reimbursement Mechanism for New Medicinal Products Addressing High Unmet Clinical Need in Gree Proposal for a Medicines Innovation Fund

    Dec 1, 2025, 00:00

  • PCR268 What Matters Most to Women in Breast Biopsy? A Discrete Choice Experiment in Italy

    Dec 1, 2025, 00:00

  • HTA319 The Impact of Clinical Evidence on the Inclusion of Non-Small Cell Lung Cancer Drugs in Brazil's Supplementary Healthcare System

    Dec 1, 2025, 00:00

  • HSD22 Characteristics and Treatment of Prevalent Heart Failure in the US: A Cross-Sectional Analysis of Annual Trends From 2014-2023

    Dec 1, 2025, 00:00

  • EPH104 Exploring Factors Associated With Online Food Delivery Behavior Among Young Adults

    Dec 1, 2025, 00:00

  • CO207 Real-World Outcomes and Economic Impact of Ribociclib in HR+/HER2- Advanced Breast Cancer: Evidence From the Portuguese REASSURE Cohort

    Dec 1, 2025, 00:00

  • CO30 Biomarker Levels in Patients With Ulcerative Colitis Post-Advanced Therapy Induction: A Real-World Survey in Europe

    Dec 1, 2025, 00:00

  • EPH256 The Use of Multiple Sleep Medications Is Highly Prevalent

    Dec 1, 2025, 00:00

  • OP20 Qualitative Insights Into Artificial Intelligence (AI) and Virtual Reality (VR) Training for Value Communication: Comparing Innovative Technologies With Traditional Methods in Pharma

    Dec 1, 2025, 00:00

  • EE268 Cost-Effectiveness of Personalized Lifestyle Interventions in Obesity/Overweight: A Systematic Review

    Dec 1, 2025, 00:00

  • CO42 Clinical and Economic Outcomes of Cannabis-Based Formulations (CBD and CBD/CBG) for Autism Spectrum Disorder (ASD): A HEOR Model Study Analysis

    Dec 1, 2025, 00:00

  • HTA8 A Long and Winding Road: An Evaluation of NICE HST Appraisals Taking Longer Than Two Years for Guidance Publication

    Dec 1, 2025, 00:00

  • HTA85 Competing Beyond the First Mover: How Late to Market Analogues Navigate Pricing and Access in Major Global Markets

    Dec 1, 2025, 00:00

  • MSR199 The HERC Database of Mapping Studies: A 2025 Update of a Live Systematic Review of Studies Predicting EQ-5D From Other Patient-Reported Outcome Measures

    Dec 1, 2025, 00:00

  • HTA256 NICE Technology Appraisal Submissions for Non-Small Cell Lung Cancer: Analysis and Insights

    Dec 1, 2025, 00:00

  • HTA30 An Irish Retrospective Analysis of Oncology Reimbursement Applications Considered by HSE Drugs Group 2022-2024

    Dec 1, 2025, 00:00

  • HPR175 Resilient Pharmaceutical Supply Chains in Times of Crisis: A Comparative Analysis of Australia, France, Italy, Spain, and UK

    Dec 1, 2025, 00:00

  • EPH199 Public Health Impact of Herpes Zoster Vaccination in Immunocompromised Adults Aged 18-49 Years in the United Kingdom

    Dec 1, 2025, 00:00

  • P50 Evaluating Personalized Care for Rare Disease: A Decision-Analytic Framework for Patient-Centered Solutions in Multiple System Atrophy

    Dec 1, 2025, 00:00

  • HSD118 Trends in Receipt of Preventive Healthcare Services from 2020-2024: US Electronic Health Records (EHR) Database Analysis of 118 Million Patients

    Dec 1, 2025, 00:00

  • EPH120 Healthcare Pathway of a Large Cohort of Patients With Chronic Obstructive Pulmonary Disease During the Last Year of Life

    Dec 1, 2025, 00:00

  • EE685 The Artificial Intelligence Era in Health Economic Modeling

    Dec 1, 2025, 00:00

  • RWD175 Study Design Trends in Registry-Based Oncology Studies: Analysis of HMA-EMA Real-World Data Catalogs

    Dec 1, 2025, 00:00

  • HPR12 Accelerating Therapeutic Innovation: Early Results From France’s Accès Direct Scheme

    Dec 1, 2025, 00:00

  • MSR162 PACE in Scotland: Utilizing Machine Learning to Assess the Importance of Patient and Clinician Engagement in HTAs in SMC

    Dec 1, 2025, 00:00

  • MSR184 Second- or Later-Line Treatments for Advanced and Metastatic Gastric Cancer: A Network Meta-Analysis Comparing Treatments to Paclitaxel

    Dec 1, 2025, 00:00

  • EE35 A Systematic Review of the Methods and Quality of Economic Evaluations for AI-Assisted Cancer Screening or Diagnosis

    Dec 1, 2025, 00:00

  • MSR186 Simulated Treatment Comparisons Using Jackknife Pseudo Values for Population-Adjusted Marginal Effect Estimation

    Dec 1, 2025, 00:00

  • MSR219 Variations in Mortality Across Clinical Trials: A Review of Statistical Methods for Adjusting for the Effect of the COVID-19 Pandemic

    Dec 1, 2025, 00:00

  • EE230 Cost-Effectiveness Evaluation of RSVpreF Vaccine for Preventing RSV Among Older Adults With High Risk Under Taiwan National Vaccination Program

    Dec 1, 2025, 00:00

  • HPR1 ComboConnect—Bridging Access Gaps in Combination Therapies: An Italian Project in Collaboration With ISPOR Italy-Rome Chapter

    Dec 1, 2025, 00:00

  • HTA27 Advocating From the Margins: How Patient Input Aligns With Broader Evidence Tolerance in HTA Within Oncology

    Dec 1, 2025, 00:00

  • EE531 Impact Of Dupilumab Treatment on Work-Related Medical Leave In Patients With Atopic Dermatitis in a Colombian Health Insurance Provider: An Observational Real-World Practice Study

    Dec 1, 2025, 00:00

  • MSR140 Machine Learning Applications in Treatment Pattern Analysis Using Real-World Data: A Scoping Review

    Dec 1, 2025, 00:00

  • SA71 Natural Language Processing for Identification of Negative Symptoms in Patients With and Without Cognitive Impairment Associated With Schizophrenia (CIAS)

    Dec 1, 2025, 00:00

  • CO227 Systematic Literature Review and Bayesian Network Meta-Analysis of Sugemalimab Plus Chemotherapy vs. Other First-Line Treatments for Metastatic Non-Small Cell Lung Cancer Without Sensitizing eGFR, ALK, ROS1, or RET Alterations

    Dec 1, 2025, 00:00

  • EE335 Disability-Associated Economic Burden Among Patients With Wilson’s Disease in South Korea: A Nationwide Cost-of-Illness Study

    Dec 1, 2025, 00:00

  • HTA104 Delayed Impact, Limited Leverage: Revenue Dynamics of Patent-Protected Drugs and the Effectiveness of Price-Volume Agreements in Germany

    Dec 1, 2025, 00:00

  • RWD157 Real-World Evidence Study on PD-L1 Testing and Use of Immuno-Oncology (IO) Treatments Among Cancer Patients in the Helsinki and Uusimaa (HUS) Region, Finland

    Dec 1, 2025, 00:00

  • HTA285 Reimbursement Trends Across Global Markets in 2024

    Dec 1, 2025, 00:00

  • MSR155 New Developments in the Psychometric Testing of the Patient-Reported Impact of Dermatological Diseases (PRIDD) Questionnaire: Responsiveness and Minimally Important Change

    Dec 1, 2025, 00:00

  • MSR63 Cost-Effectiveness Modeling Based on a Clinical Trial Re-analysis Using Multimodal Machine Artificial Intelligence Methodology: Predicting Which Patients May Benefit Most From the Addition of Tremelimumab to Durvalumab Plus Chemothera ...

    Dec 1, 2025, 00:00

  • HTA369 Who Speaks For Europe? A Country-Level Analysis Of Representation And Expertise In EU Health Technology Assessment Joint Bodies

    Dec 1, 2025, 00:00

  • HTA181 How the EU JCA Could Interface With Regional Pricing Alliances (BeNeLuxA, Nordic Forum, Valletta Group) and EU-Level Procurement Under the Critical Medicines Act

    Dec 1, 2025, 00:00

  • MSR92 Evaluating the Conceptual Structure of the Barriers to Preexposure Prophylaxis (PrEP) Access Survey: A Confirmatory Item Factor Analysis

    Dec 1, 2025, 00:00

  • EE696 The Costs of Loneliness-Related Health Consequences in Finland

    Dec 1, 2025, 00:00

  • PCR264 Variability in Health Utility Scores in Pancreatic Cancer: Findings From a Targeted Literature Review

    Dec 1, 2025, 00:00

  • PCR44 CKDL5 Deficiency Disorder: Caregiver’s Perception of Clinical Symptoms Disease Management and Its Impact on Quality-of-life

    Dec 1, 2025, 00:00

  • MT22 Global Evaluation of Flexible Cysto-Nephroscope Usage Patterns in Percutaneous Nephrolithotomy Procedures

    Dec 1, 2025, 00:00

  • EPH187 Premature Mortality and Lost Productivity Due to HPV-Related Cancers in Europe

    Dec 1, 2025, 00:00

  • PCR241 The Reliability and Validity of the Greek Version of the Pediatric Quality of Life Inventory™ 30 Duchenne Muscular Dystrophy Module in Children With Duchenne Muscular Dystrophy

    Dec 1, 2025, 00:00

  • HTA250 Navigating Uncharted Waters: Challenge of Anticipating Technologies Subject to Environmental Considerations in Future HTA

    Dec 1, 2025, 00:00

  • OP19 Qualitative Evaluation of an AI Tool for Opportunistic Detection of Vertebral Fractures in the National Health Service

    Dec 1, 2025, 00:00

  • RWD2 A Hierarchical Algorithm to Identify Pregnancy Start and Duration Using Structured EHR Data

    Dec 1, 2025, 00:00

  • PT38 Efficacy and Safety of Nalbuphine Compared With Analgesics for Moderate to Severe Postoperative Pain: A Systematic Review and Network Meta-Analysis

    Dec 1, 2025, 00:00

  • HPR75 Evaluating the Costs and Benefits of Innovative Pricing and Payment Models in Europe

    Dec 1, 2025, 00:00

  • HTA83 Comparing Risk of Bias Assessment Requirements Between the EU JCA and European HTA Agencies

    Dec 1, 2025, 00:00

  • HTA169 Harnessing Generative Artificial Intelligence for Global Value Dossier Development

    Dec 1, 2025, 00:00

  • HTA125 Ensuring Greater Acceptance of Minimal Residual Disease Negativity in Health Technology Assessments in Multiple Myeloma: Key Barriers and Opportunities

    Dec 1, 2025, 00:00

  • EE481 Global Economic Burden of Metabolic Dysfunction-Associated Steatohepatitis With Cirrhosis: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • EPH136 Impact of RSV Infection on Acute Otitis Media Burden in Young Children Beyond Their First Year of Life in Japan

    Dec 1, 2025, 00:00

  • EE151 Conceptualizing an Economic Model Structure for Parkinson's Disease

    Dec 1, 2025, 00:00

  • SA45 Gaps in JCA Guidance for Systematic Literature Reviews: A Comparative Review with Cochrane, EUnetHTA, and Major HTA Agencies' Standards

    Dec 1, 2025, 00:00

  • EPH10 A Systematic Literature Review to Identify Risk Factors and Symptoms of Long COVID-19 in Adult Indian Patients

    Dec 1, 2025, 00:00

  • EPH118 (HCRU)/Costs and Epidemiology of Patients With ADHD in Germany: A Claims Data Study (HEDDA)

    Dec 1, 2025, 00:00
  • 1
  • 2 (current)
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • »